The following interviews with kidney cancer experts were recorded by Practice Update and UroTodayat the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019.

Pembrolizumab and axitinib as first-line therapy

Key data from ASCO GU 2019 on mRCC

Frontline RCC treatment from ASCO GU 2019: Practice implications

Pembrolizumab for non-clear cell RCC

Tivozanib for refractory advanced RCC

Patient perspectives on cytoreductive nephrectomy after the CARMENA trial